Register Login

Novocure Ltd (NVCR)

  • Event
  • June 03, 2022, 12:01 UTC

(85% Positive) NovoCure Limited (NVCR) Provides Update on changes for a historically difficult to treat cancer

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 3:49 a.m.

    📋 NovoCure Limited (NVCR) - Clinical Trial Update

    Filing Date: 2022-06-03

    Accepted: 2022-06-03 08:01:18

    Event Type: Clinical Trial Update

    Event Details:

    Novocure Ltd (NVCR) Announces Clinical Trial Update Novocure Ltd (NVCR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: changes, survival
    • Diseases/Conditions: a historically difficult to treat cancer
    • Clinical Stage: Phase 2, phase 2
    • Collaboration: First-Line Treatment of Gastric Cancer Confirmed

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Novocure Ltd
    • CIK: 0001645113
    • Ticker Symbol: NVCR
    • Period End Date: 2022-06-03
    • Document Type: 8-K

Search

News categories